← The SEC Ephemeris: the whole map
Xbrane Biopharma AB We have completed our review of this application
In the graph: all 1 documents (3 pages).
- Application
- BLA 761187
- Ticker
- Xbrane Biopharma AB
- Product
- We have completed our review of this application
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- April 19, 2024
From FDA letters and SEC filings. Not investment or medical advice.